

PRESS RELEASE

Gothenburg, Sweden

August 24, 2022, 07:00 (CEST)

Publication of Interim Report January – June 2022
BICO Group AB 559050-5052 (NASDAQ STOCKHOLM: BICO).
Strong sales despite external challenges

BICO is the future of life-saving treatments. We are reducing the organ shortage and speeding up drug development by providing accessible life science solutions that combine biology and technology.

**APRIL – JUNE 2022
(COMPARED WITH APRIL – JUNE 2021)**

- Net sales amounted to MSEK 537.6 (293.1), which corresponds to an increase of 83% (628) compared to the corresponding period previous year.
- Organic growth for the period amounted to 7% (95).
- EBITDA amounted to MSEK -62.9 (10.6), corresponding to a margin of -11.7% (3.6).
- Adjusted EBITDA amounted to MSEK 11.1 (21.5), corresponding to a margin of 2.1% (7.3)
- Net profit/loss for the period amounted to MSEK 43.1 (-50.5), corresponding to earnings per share before and after dilution of SEK 0.68 (-0.89).
- The gross margin amounted to 73.0% (69.1). The gross margin structure in the acquired companies 2021 varies depending on the product mix.

**JANUARY – JUNE 2022
(COMPARED WITH JANUARY – JUNE 2021)**

- Net sales amounted to MSEK 1,014.8 (422.6), which corresponds to an increase of 140% (440) compared to the corresponding period previous year.
- Organic growth for the period amounted to 21% (79).
- EBITDA amounted to MSEK -82.3 (-24.3), corresponding to margin of -8.1% (-5.8).
- Adjusted EBITDA amounted to MSEK 17.1 (8.7), corresponding to a margin of 1.7% (2.1).
- Net profit/loss for the period amounted to MSEK -0.4 (-98.3), corresponding to earnings per share before and after dilution of SEK 0.00 (-1.78).
- The gross margin amounted to 73.4% (72.5). The gross margin structure in the acquired companies 2021 varies depending on the product mix.

“The company pulse is strong. We have a tremendous portfolio of products and services that contribute to the future of life-saving treatments.”

ERIK GATENHOLM / PRESIDENT & CEO

Q2 KEY TAKEAWAYS

- Highest turnover ever
- Cash flow improvement measures
- Strengthened finance processes
- Continued success in innovation
- Focus on operational efficiency and acquisition synergies
- Cost reduction program decided after the end of the period

INVITATION TO PRESENTATION:

Join us for combined presentation audiocasts and telephone conferences with the opportunity to ask questions at 09:00 CEST and 16:00 CEST on August 24, 2022, with President & CEO Erik Gatenholm and Interim CFO Mikael Engblom.

The presentation audiocasts will be accessible via the following links:

Morning audiocast, at 09:00 CEST:
<https://tv.streamfabriken.com/bico-q2-2022-am>

To participate via telephone, please call any of the following numbers:

SE: +46 8 505 163 86
UK: +44 203 198 4884
US: +1 412 317 6300

PIN for all numbers: 3144420#

Afternoon audiocast, at 16:00 CEST:

<https://tv.streamfabriken.com/bico-q2-2022-pm>

To participate via telephone, please call any of the following numbers:

SE: +46 8 505 163 86
UK: +44 203 198 4884
US: +1 412 317 6300

PIN for all numbers: 3505431#

The presentation will also be available on the company's website:
<https://bico.com/investors/financials/financial-reports-and-presentations/>

FOR FURTHER INFORMATION, PLEASE CONTACT:

Erik Gatenholm / President and CEO BICO Group AB
Phone: +46 732 67 00 00 / E-mail: eg@bico.com

Mikael Engblom / Interim Group CFO BICO Group AB
Phone: +46 0709-91 86 04/ E-mail: me@bico.com

Åsa Hillsten / SVP & Head of Investor Relations BICO Group AB
Phone: +46 700 81 81 17 / E-mail: ash@bico.com

This information is information that BICO Group AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Market Act. The information was submitted for publication, through the agency of the contact persons, on 24 August 2022 at 07:00 CET.